methyl 4-(methylsulfonamidomethyl)benzoate | 152122-32-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: methyl 4-(methylsulfonamidomethyl)benzoate
• 英文别名: Methyl 4-[(methanesulfonamido)methyl]benzoate；methyl 4-(methanesulfonamidomethyl)benzoate
• CAS: 152122-32-2
• 化学式: C₁₀H₁₃NO₄S
• mdl: MFCD20539904
• 分子量: 243.284
• InChiKey: PUBAASALCFKMJT-UHFFFAOYSA-N

物化性质

• 沸点：
  399.1±52.0 °C(Predicted)
• 密度：
  1.280±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  16
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  80.8
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  methyl 4-(methylsulfonamidomethyl)benzoate 在 (1-cyano-2-ethoxy-2-oxoethylidenaminooxy)dimethylaminomorpholinocarbenium hexafluorophosphate 、 N,N-二异丙基乙胺 、 sodium hydroxide 作用下， 以 四氢呋喃 、 1,4-二氧六环 为溶剂， 反应 18.0h， 生成 N-{4-[(2-benzoylhydrazino)carbonyl]benzyl}methanesulfonamide
  参考文献：
  名称：

  Systematic variation of the benzenesulfonamide part of the GluN2A selective NMDA receptor antagonist TCN-201

  摘要：

  GluN2A subunit containing N-methyl-D-aspartate receptors (NMDARs) are highly involved in various physiological processes in the central nervous system, but also in some diseases, such as anxiety, depression and schizophrenia. However, the role of GluN2A subunit containing NMDARs in pathological processes is not exactly elucidated. In order to obtain potent and selective inhibitors of GluN2A subunit containing NMDARs, the selective negative allosteric modulator 2 was systematically modified at the benzenesulfonamide part. The activity of the test compounds was recorded in two electrode voltage clamp experiments using Xenopus laevis oocytes expressing exclusively NMDARs with GluN1a and GluN2A subunits. It was found that halogen atoms in 3-position of the benzenesulfonamide part result in high GluN2A antagonistic activity. With an IC50 value of 204 nM the 3-bromo derivative 5i (N-{4-[(2-benzoylhydrazino) carbonyl]benzyl}-3-bromobenzenesulfonamide) has 2.5-fold higher antagonistic activity than the lead compound 2 and represents our new lead compound. (C) 2017 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2017.02.018
• 作为产物：
  描述：

  4-氨甲基苯甲酸 在 氯化亚砜 、 N,N-二异丙基乙胺 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 反应 32.0h， 生成 methyl 4-(methylsulfonamidomethyl)benzoate
  参考文献：
  名称：

  Systematic variation of the benzenesulfonamide part of the GluN2A selective NMDA receptor antagonist TCN-201

  摘要：

  GluN2A subunit containing N-methyl-D-aspartate receptors (NMDARs) are highly involved in various physiological processes in the central nervous system, but also in some diseases, such as anxiety, depression and schizophrenia. However, the role of GluN2A subunit containing NMDARs in pathological processes is not exactly elucidated. In order to obtain potent and selective inhibitors of GluN2A subunit containing NMDARs, the selective negative allosteric modulator 2 was systematically modified at the benzenesulfonamide part. The activity of the test compounds was recorded in two electrode voltage clamp experiments using Xenopus laevis oocytes expressing exclusively NMDARs with GluN1a and GluN2A subunits. It was found that halogen atoms in 3-position of the benzenesulfonamide part result in high GluN2A antagonistic activity. With an IC50 value of 204 nM the 3-bromo derivative 5i (N-{4-[(2-benzoylhydrazino) carbonyl]benzyl}-3-bromobenzenesulfonamide) has 2.5-fold higher antagonistic activity than the lead compound 2 and represents our new lead compound. (C) 2017 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2017.02.018

文献信息

• 1-PHENYL-2-PYRIDINYL ALKYL ALCOHOL DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS
  申请人：CHIESI FARMACEUTICI S.p.A.

  公开号：US20140155391A1

  公开（公告）日：2014-06-05

  Compounds of formula (I) described herein are inhibitors of the phosphodiesterase 4 (PDE4) enzyme and are useful for the prevention and/or treatment of an allergic disease state or a disease of the respiratory tract characterized by airway obstruction.

  本文描述的化合物（I）的公式是磷酸二酯酶4（PDE4）酶的抑制剂，可用于预防和/或治疗由气道阻塞特征的过敏病状态或呼吸道疾病。
• Imidazole derivatives and their use as cytokine inhibitors
  申请人：SmithKline Beecham Corporation

  公开号：US05686455A1

  公开（公告）日：1997-11-11

  As cytokine inhibitors 2,4,5-triarylimidazole compounds and compositions for use as cytokine inhibitors.

  作为细胞因子抑制剂的2,4,5-三芳基咪唑化合物和组合物，用作细胞因子抑制剂。
• [EN] IMIDAZOLE DERIVATIVES AND THEIR USE AS CYTOKINE INHIBITORS
  申请人：SMITHKLINE BEECHAM CORPORATION

  公开号：WO1993014081A1

  公开（公告）日：1993-07-22

  (EN) Novel 2,4,5-triarylimidazole compounds and compositions for use in therapy.(FR) Nouveaux composés 2,4,5-triarylimidazole et compositions s'utilisant en thérapie.

  (EN) 新型2,4,5-三芳基咪唑化合物及其在治疗中的应用组合物。 (FR) 新型2,4,5-三芳基咪唑化合物及其在治疗中的应用组合物。
• Novel compounds
  申请人：SmithKline Beecham Corporation

  公开号：US20030064997A1

  公开（公告）日：2003-04-03

  Novel 2,4,5-triaryl imidazole compounds and compositions for use in therapy.

  小说2,4,5-三芳基咪唑化合物及其在治疗中的应用组成物。
• Benzofuran compounds, compositions and methods for treatment and prophylaxis of hepatitis C viral infections and associated diseases
  申请人：——

  公开号：US20040162318A1

  公开（公告）日：2004-08-19

  The present invention relates to novel benzofuran derivatives and analogs, as well as compositions containing the same and to the use thereof for the treatment or prophylaxis of viral infections and diseases associated therewith, particularly those viral infections and associated diseases caused by the hepatitis C virus.

  本发明涉及新型苯并呋喃衍生物和类似物，以及含有它们的组合物，以及将它们用于治疗或预防与病毒感染有关的疾病，特别是由丙型肝炎病毒引起的病毒感染和相关疾病的用途。